Sickle Cell Disease Cured With Partial-Match Bone Marrow

September 25, 2012

David Porter, MD, a professor in the division of Hematology-Oncology and director of Blood and Marrow Transplantation in the Abramson Cancer Center, is quoted in a Medscape article about a new study showing that haploidentical bone marrow transplant -- so called "half-match" transplants – can cure sickle cell disease (SCD) in adults if combined with high-dose cyclophosphamide after the procedure to reduce risk of graft-versus-host-disease. "Finding well-matched donors for all patients who might benefit remains a challenge, and this issue is particularly acute for minorities, who may be underrepresented on marrow registries," he said. "Most patients will have mismatched or half-matched family members, but historically, toxicity, particularly from GVHD, has been limiting, making haploidentical transplant impractical for many patients."

See more at Medscape.